To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings

Release Date: 27/11/2020 11:00
Code(s): MEI     PDF:  
Wrap Text
TR-1: Standard form for notification of major holdings

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")

27 November 2020

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of                                        Mediclinic International plc
existing shares to which voting rights are attached:

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights                                                                             X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):

3. Details of person subject to the notification obligation
Name                                                                                   Genesis Investment Management, LLP
City and country of registered office (if applicable)                                          21 Grosvenor Place, London

4. Full name of shareholder(s) (if different from 3.)
Name                                                                                                                  N/A
City and country of registered office (if applicable)

5. Date on which the threshold was crossed or                                                          24th November 2020
reached:

6. Date on which issuer notified (DD/MM/YYYY):                                                         26th November 2020

7. Total positions of person(s) subject to the notification obligation

                                         % of voting       % of voting rights         Total of both in   Total number of
                                         rights attached   through financial          % (8.A + 8.B)      voting rights of
                                         to shares         instruments                                   issuer
                                         (total of 8. A)   (total of 8.B 1 + 8.B 2)
                                                                                                                                
Resulting situation on the date on       4.99%                                        4.99%              737,243,810
which threshold was crossed or
reached 
Position of previous notification (if    5.01%                                        5.01%
applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares
Class/type of                     Number of voting rights                           % of voting rights
shares
ISIN code (if possible)    Direct                   Indirect                 Direct                     Indirect
                           (Art 9 of Directive      (Art 10 of Directive     (Art 9 of Directive        (Art 10 of Directive
                           2004/109/EC)             2004/109/EC)             2004/109/EC) (DTR5.1)      2004/109/EC)
                           (DTR5.1)                 (DTR5.2.1)                                          (DTR5.2.1)
GB00B8HX8Z88               36,787,877                                        4.99%

SUBTOTAL 8. A                          36,787,877                                        4.99%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial            Expiration       Exercise/                    Number of voting rights      % of voting rights
instrument                   date             Conversion Period            that may be acquired if
                                                                           the instrument is
                                                                           exercised/converted.

                                              SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
Type of financial   Expiration       Exercise/         Physical or         Number of         % of voting rights
instrument          date             Conversion        cash                voting rights
                                     Period            settlement

                                                       SUBTOTAL
                                                       8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not        X
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)
                                                                                                                    
Name                             % of voting rights if it         % of voting rights           Total of both if it equals
                                 equals or is higher than         through financial            or is higher than the
                                 the notifiable threshold         instruments if it equals     notifiable threshold
                                                                  or is higher than the
                                                                  notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information

Place of completion                                                                                      London, England
Date of completion                                                                                    26th November 2020

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions 
in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates (" UAE").

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such
a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients,
medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 September 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 17 day case clinics
and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland with more than 1
900 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub -
acute and specialised hospitals and 11 day case clinics (four of which operated by Intercare) across South Africa, and
more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under a management contracts Mediclinic
Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-
2022.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with secondary listings
on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
                                                                                                                
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group base d in the
United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd                                                                                               

Date: 27-11-2020 11:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story